Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk

International Journal of Clinical Practice

Volumn 65, Issue 2, 2011, Pages 134-147

  Billups, K L ^a   Miner, M M ^b   Wierzbicki, A S ^c   Jackson, G ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BROWN UNIVERSITY   (United States)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d LONDON BRIDGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CALCIUM; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TRIACYLGLYCEROL; VITAMIN D;

CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ERECTILE DYSFUNCTION; GENDER; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK FACTOR; STROKE; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CALCINOSIS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, HDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; KIDNEY DISEASES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MINORITY GROUPS; OBESITY, ABDOMINAL; RISK ASSESSMENT; RISK FACTORS; SEDENTARY LIFESTYLE; TESTOSTERONE; VASODILATION; VITAMIN D; WAIST CIRCUMFERENCE;

EID: 78751518194     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02564.x     Document Type: Review

References (104)

1. Marma AK, Berry JD, Ning H, et al. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults findings from the National Health and Nutrition Examination Survey 2003-2006. Circ Cardiovasc Qual Outcomes 2010; 3: 4-5.
2. Traish AM, Saad F, Guay AT,. The dark side of testosterone deficiency: II. type 2 diabetes & insulin resistance. J Androl 2009; 30: 23-32.
3. Traish AM, Guay AT, Feeley R, Saad F,. The dark side of testosterone deficiency: I. metabolic syndrome & erectile dysfunction. J Androl 2009; 30: 10-22.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-97.
5. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
6. Ferket BS, Colkesen EB, Visser JJ, et al. Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med 2010; 170: 27-40. Review.
7. Clark LT, Ferdinand KC, Flack JM, et al. Coronary heart disease in african americans. Heart Disease 2001; 3: 97-108.
8. Clark LT, Maki KC, Galant R, et al. Ethnic differences in achievement of cholesterol treatment goals results from the national cholesterol education program evaluation project utilizing novel E-technology II. J Gen Intern Med 2006; 21: 320-6.
9. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368: 919-28. (Pubitemid 44331360)
10. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010; 375: 181-3.
11. Grundy S,. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-36.
12. Radbill B, Murphy B, Leroith D,. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc 2008; 83: 1373-81.
13. Hall DW, Clark LT, Wenger NK, et al. Original reports: cardiovascular disease the metabolic syndrome in African Americans: a review. Ethn Dis 2003; 13: 414-28.
14. Rathmann W, Haastert B, Herder C, et al. Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000 Int J Obes 2007; 31: 770-6.
15. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
16. Snijder MB, Heine RJ, Seidell JC, et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women. The Hoorn study. Diabetes Care 2006; 29: 2498-503.
17. Silvestro A, Brevetti G, Schiano V, et al. Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification. Thromb Haemost 2005; 93: 559-63.
18. Nikoobakht M, Nasseh H, Pourkasmaee M,. The relationship between lipid profile and erectile dysfunction. Int J Impot Res 2005; 17: 523-6.
19. Burke JP, Jacobson DJ, McGree ME, et al. Diabetes and sexual dysfunction: results from the Olmsted County Study of Urinary Symptoms and health status among men. J Urol 2007; 177: 1438-42.
20. Billups KL, Kaiser DR, Kelly AS, et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003; 15: 231-6.
21. Feldman HA, Goldstein I, Hatzichristou DJ, et al. Impotence and its medical and psychological correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54-61.
22. Jackson G, Montorsi P, Adams MA, et al. Cardiovascular aspects of sexual medicine. J Sex Med 2010; 7: 1608-26.
23. Nawawi H, Osman NS, Annuar R, et al. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 2003; 169: 283-91.
24. Naya M, Tsukamoto T, Morita K, et al. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res 2007; 30: 541-8.
25. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 2006; 27: 2640-8.
26. Ridker PM, Danielson E, Fonseca FA, et al., JUPITER Study Group. Rosuvastatin to prevent events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
27. Giugliano F, Esposito K, Di Palo C, et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 2004; 27: 665-9.
28. Yusuf S, Hawken S, Ounpuu S, et al. Effects of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): Case control study. Lancet 2004; 364: 937-52. (Pubitemid 39208455)
29. Mente A, Yusuf S, Islam S, et al. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol 2010; 55: 2390-8.
30. Herrera V, Casas J, Miranda J, et al. Interethnic differences in the accuracy of anthropometric indicators of obesity in screening for high risk of coronary heart disease. Int J Obes (Lond) 2009; 33 (5): 568-76.
31. Hoffman DJ, Wang Z, Gallagher D, Heymsfield SB,. Comparison of visceral adipose tissue mass in adult African Americans and whites. Obes Res 2005; 13: 66-74.
32. Mora S, Musunuru K, Blumenthal RS,. The clinical utility of high sensitive C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 2009; 55: 219-28.
33. Musunuru K, Kral BG, Blumenthal RS, Fuster V, et al. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clinical Pract Cardiovacs Med 2008; 5: 621-35.
34. Carroll JF, Fulda KG, Chiapa AL, et al. Impact of race/ethnicity on the relationship between visceral fat and inflammatory biomarkers. Obesity (Silver Spring) 2009; 17: 1420-7.
35. Pederseb TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL Study: a randomized controlled trial. JAMA 2005; 294: 2437-45.
36. Kastelein JJ, van der Steeg WA, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 3002-9.
37. Clarenbach JJ, Grundy SM, Palacio N, Lena Vega G,. Relationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome. Journal of Investigative Med 2007; 55: 237-47.
38. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy. J Intern Med 2006; 259: 247-58.
39. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk. J Am Coll Cardiol 2008; 51: 1512-24.
40. Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: The MESA Study. Arch Intern Med 2008; 168: 1333-9.
41. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. NEJM 2008; 358: 1336-45.
42. The Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300: 197-208.
43. Vlachopoulos C, Aznaouridis K, Stefanadis C,. Prediction of cardiovascular events and all cause mortality with arterial stiffness: a systematic review and Meta analysis. J Am Coll Cardiol 2010; 55: 1318-27.
44. Zheng ZJ, Rosamond WD, Chambless LE, et al. Lower extremity arterial disease assessed by ankle-brachial index in a middle aged population of African Americans and whites: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Prev Med 2005; 29 (5Suppl. 1): 42-9.
45. Arena R, Fei DY, Arrowood J, Kraft KA,. Influence on aerobic fitness on aortic stiffness in apparently healthy Caucasian and African-American subjects. Int J Cardiol 2007; 122: 202-6.
46. Cooke JP,. The endothelium: a new target for therapy. Vasc Med 2000; 5: 49-53.
47. Lekakis J, Papamichael C, Vemmos C, et al. Effects of acute cigarette smoking on endothelium-dependent arterial dilatation in normal subjects. Am J Cardiol 1998; 81: 1225-8.
48. Higashi Y, Sasaki S, Nakagawa K, et al. Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension. Am J Hypertens 2001; 14: 1038-45.
49. Suzuki T, Hirata K, Elkind MSV, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the northern manhattan study (NOMAS). Am Heart J 2008; 156: 405-10.
50. Mata-Greenwood E, Chen D-B,. Racial differences in nitric oxide-dependent vasorelaxation. Reproductive Sciences 2008; 15: 9-25.
51. Cardillo C, Kilcoyne CM, Cannon RO III, Panza JA,. Attenuation of a cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation 1999; 99: 90-5.
52. Stein CM, Lang CC, Nelson R, Brown M, Wood AJ,. Vasodilation in black Americans: attenuated nitric-oxide mediated responses. Clin Pharmacol Ther 1997; 62: 436-43.
53. Androne AS, Hyrniewicz K, Hudaihed A, et al. Comparison of metabolic vasdilation in response to exercise and ischemia and endothelium-dependent flow-mediated dilation in African American versus non-african-american patients with chronic heart failure. Am J Cardiol 2006; 97: 685-9.
54. Fiscella K, Franks P,. Vitamin D, race, and cardiovascular mortality: findings from a national us sample. Ann of F Med 2010; 8: 11-8.
55. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-9.
56. Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ,. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008; 102: 1540-4.
57. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010; 31: 1591-8.
58. Venuraju SM, Yerramasu A, Corder R, Lahiri A,. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010; 19: 2049-61.
59. Anantharaman P, Schmidt RJ,. Sexual function in chronic kidney disease. Adv Chronic Kidney Dis. 2007; 14: 119-25. Review.
60. Parikh NI, Hwang SJ, Larson MG, Levy D, Fox CS,. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol 2008; 102: 47-53.
61. Foster MC, Hwang SJ, Larson MG, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007; 167: 1386-92.
62. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114: 201-8.
63. Billups KL, Kaiser DR, Kelly AS, et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003; 15: 231-6.
64. Ma RC, So WY, Yang X, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008; 51: 2045-50.
65. Wierzbicki AS, Solomon H, Lumb PJ, Lyttle K, Lambert-Hammill M, Jackson G,. Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis 2006; 185: 421-5.
66. Elesber AA, Solomon H, Lennon RJ, et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006; 27: 824-31.
67. Thompson IM, Tamgen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA,. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2296-3002.
68. Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am J Cardiol 2008; 51: 2040-4.
69. Ma RC, So WY, Yang X, et al. Erectile dysfunction predicts coronary artery disease in type 2 diabetics. J Am Coll Cardiol 2008; 51: 2045-50.
70. Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005; 47: 80-5.
71. Fonseca V, Jawa A,. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: Common pathways and treatments? Am J Cardiol 2005; 96: 13M-8M.
72. Vinik A, Richardson D,. Erectile dysfunction in diabetes. Diabetes Rev 1998; 6: 16-33.
73. Fedele D, Coscelli C, Santeusanio F, et al., for the Gruppo Italiano Studio Deficit Erecttile nei Diabetici. Erectile dysfunction in diabetic subjects in Italy. Diabetes Care 1998; 21: 1973-7.
74. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Imp Res 2000; 12: 305-11.
75. Bacon CG, Hu FB, Giovannucci E, et al. Association and type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002; 25: 1458-63.
76. Rhoden EL, Ribeiro EP, Riedner CE, et al. Glycosolated hemoglobin levels and the severity of erectile function in diabetic men. BJU Int 2005; 95: 615-7.
77. Gazzaruso C, Pujia A, Solerte SB, et al. Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. In J Impot Res 2006; 18: 311-5.
78. Inman BA, St. Sauver JL, Jacobson DJ, et al. A population-based longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84: 108-13.
79. Miner M,. Erectile dysfunction and the "window of curability": a harbinger of cardiovascular events (editorial). Mayo Clin Proc 2009; 84: 102-4.
80. Montorsi P, Montorsi F, Schulman CC,. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder (editorial)? Eur Urol 2003; 44: 352-4.
81. Guiliano F,. New horizons in erectile and endothelial dysfunction research and therapies. Int J Imp Res 2008; 20: S2-8.
82. Guay AT,. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol and Metab Clinic of NA 2007; 36: 453-63.
83. Billups K, Bank AJ, Padma-Nathan H, Katz S, Williams R,. Erectile dysfunction is a marker for cardiovascular disease: results of the Minority NiHealth Institute Expert Advisory Panel. J Sex Med 2005; 2: 40-50.
84. O'Rourke MF, Hashimoto J,. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 2007; 50: 1-13.
85. Kaiser DR, Billups KL, Bank AL, et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179-84.
86. Shabsigh R,. Correlation between erectile dysfunction and metabolic syndrome. In:, Sadovsky R, ed. Heart of the Matter: Erectile Dysfunction as an Early Sign of Vasculopathy. Livingston, NJ: CogniMed Inc, 2005: 14-21.
87. Saigal CS, Wessels H, Pace J, et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006; 166: 207-12.
88. Smith JF, Caan BJ, Sternfield B, et al. Racial disparities in erectile dysfunction among participants in the California men's health study. J Sex Med 2009; 6: 3343-9.
89. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, et al. Prevalence of hypogonadism in males at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762-9.
90. Miner M, Canty D, Shabsigh R,. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices. Postgrad Med 2008; 120): 130-52.
91. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H,. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658-63.
92. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR,. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-5.
93. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease and cancer in men: European prospective investigation in cancer in Norfolk (EPIC-norfolk) prospective population study. Circulation 2007; 116: 2694-701.
94. Harman SM,. Testosterone in older men after the Institute of Medicine Report: where do we go from here? Climacteric 2005; 8: 124-35.
95. Basaria S, Coviello A, Travison T, et al. Adverse Events Associated with Testosterone Administration. N Engl J Med 2010; 363: 109-22. Epub 2010 Jun 30.
96. Gapstur SM, Gann PH, Kopp P, et al. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1041-7.
97. Litman HJ, Bhasin S, Link CL, et al. Serum androgen levels in black, Hispanic and white men. J Clin Endocrinol Metab 2006; 91: 4326-34.
98. Schouten BWV, Bohnen AM, Bosch JLHR, Bernsen RMD, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res 2008; 20: 92-9.
99. Schouten BWV, Bohnen AM, Dohle GR, Groeneveld F, et al. Risk factors for deterioration of erectile function: the Krimpen study. Int J Androl 2007; 32: 166-75.
100. Rosen R, Cappelleri J, Smith M, Lipsky J, Peña B,. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-26.
101. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-42.
102. Mohammed O, Freundlich RE, Dakik HK, et al. The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism. Int J Impot Res 2010; 22: 20-4. (published online 6 August 2009).
103. Jackson G, Montorsi P, Adams MA, et al. Cardiovascular aspects of sexual mediciine. J Sex Med 2010; 7: 1608-26.
104. Jackson G, Boon N, Eardley I, Kirby M, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract 2010; 64: 848-57.